



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/620,242	07/15/2003	Ricky Ulrich	003/267/SAP	8917

7590 03/16/2006

ATTN: MCMR-JA (Ms. Elizabeth Arwine- PATENT ATTY)  
U. S. Army Medical Research and Materiel Command  
504 Scott Street  
Fort Detrick, MD 21702-5012

EXAMINER

NAVARRO, ALBERT MARK

ART UNIT PAPER NUMBER

1645

DATE MAILED: 03/16/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/620,242

Applicant(s)

ULRICH ET AL.

Examiner

Mark Navarro

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-63 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-63 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____.  |

***Election/Restrictions***

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-3, 19, 21, 23, 26, 28, 30 and 32, drawn to DNA encoding a *B. mallei* AHS protein, classified in class 536, subclass 23.7.
- II. Claims 4-8, drawn to DNA encoding a *B. mallei* LuxR transcription regulator, classified in class 536, subclass 23.7.
- III. Claims 9-12, 20, 22, 24-25, 27, 29 and 31, drawn to DNA encoding a *B. pseudomallei* AHS protein, classified in class 536, subclass 23.7.
- IV. Claim 13-18, drawn to DNA which encodes a *B. pseudomallei* LuxR transcriptional regulator, classified in class 536, subclass 23.7.
- V. Claims 33 and 37, drawn to a *B. mallei* AHS peptide, classified in class 530, subclass 350.
- VI. Claims 34 and 38, drawn to a *B. mallei* LuxR peptide, classified in class 530, subclass 350.
- VII. Claims 35 and 39, drawn to a *B. pseudomallei* AHS peptide, classified in class 530, subclass 350.
- VIII. Claims 36 and 40, drawn to a *B. pseudomallei* LuxR peptide, classified in class 530, subclass 350.
- IX. Claims 41-42, drawn to an antibody, classified in class 530, subclass 387.1.
- X. Claim 43, drawn to a method for screening agents which reduce *B. mallei* virulence, classified in class 435, subclass 7.1.

- XI. Claims 44-45, drawn to drugs which inhibit *B. mallei* Bmal3 enzyme activity, classified in class 514, subclass 2.
- XII. Claim 46, drawn to a method of detecting bpml2 via PCR, classified in class 435, subclass 6.
- XIII. Claim 47, drawn to kits comprising primers specific for bmal3, classified in class 435, subclass 975.
- XIV. Claim 48, drawn to methods for treatment of *B. mallei*, classified in class 424, subclass 184.1.
- XV. Claims 49-54, 56, and 58-60, drawn to a *B. mallei* strain with a mutated Bmal3 gene, classified in class 435, subclass 252.3.
- XVI. Claims 55 and 57, drawn to a *B. pseudomallei* strain with a mutated bpml3 gene, classified in class 435, subclass 252.3.
- XVII. Claim 61, drawn to a method of eliciting a *B. mallei* immune response, classified in class 424, subclass 93.1.
- XVIII. Claim 62, drawn to a kit of primers specific for *Burkholderia*, classified in class 435, subclass 975.
- XIX. Claim 63, drawn to a method for distinguishing between *B. mallei* and *B. pseudomallei*, classified in class 435, subclass 7.4.

**Additionally Groups I-XIX are further restricted as set forth in MPEP 803.04, which sets forth that biological molecules with distinct sequences are distinct inventions. Accordingly, Applicant is restricted to a single SEQ ID NO for examination.**

The inventions are distinct, each from the other because of the following reasons:

Inventions I-IV are all distinct as they are all DNA molecules encoding separate proteins from separate organisms with a distinct structure.

Invention I-IV, drawn to DNA, and Inventions V-VIII, drawn to polypeptides are distinct since they are products with different structure and biological properties. The protein is made of amino acids whereas the nucleic acid consists of nucleotides. Further methods known in the art used to make the polypeptide require different reagents and parameters from the methods of making the nucleic acid encoding the protein and the method of making the polypeptide does not require the nucleic acid. For instance, the protein can be made by Merrifield chemical synthesis or affinity chromatography.

Inventions V-VIII are all distinct as they are all molecules with a distinct primary, secondary and tertiary structure.

Invention IX, drawn to an antibody is distinct from Inventions I-VIII and X-XIX since it has an inherent affinity, avidity, and specificity for a given epitope.

Invention X, drawn to methods of screening agents is distinct from Inventions I-IX and XI-XIX since it requires additional biological reagents and parameters for detecting the agent.

Invention XI, drawn to drugs is distinct from Inventions I-X and XII-XIX since it has a unique primary, secondary and tertiary structure.

Invention XII, drawn to methods of detecting *bpml2* via PCR is distinct from Inventions I-XI and XIII-XIX since it requires additional biological reagents and parameters for detecting *bpml2*.

Invention XIII, drawn to primers specific for *bmal3* is distinct from Inventions I-XII and XIV-XIX since it requires specific probes for *bmal3*.

Invention XIV, drawn to methods for treatment of *B. mallei* is distinct from Inventions I-XIII and XV-XIX since it requires additional biological reagents and parameters.

Invention XV, drawn to a *B. mallei* strain with a mutated *Bmal3* gene, is distinct from Inventions I-XIV and XVI-XIX since it requires a specific mutation.

Invention XVI, drawn to *B. pseudomallei* strain with a mutated *bpml3* is distinct from Inventions I-XV and XVII-XIX since it requires a specific mutation.

Invention XVII, drawn to method of eliciting a *B. mallei* immune response is distinct from Inventions I-XVI and XVIII-XIX since it requires additional biological reagents and parameters.

Invention XVIII, drawn to kit of primers specific for *Burkholderia* is distinct from Inventions I-XVII and XIX since it requires specific probes for *Burkholderia*.

Invention XIX, drawn to a method for distinguishing between *B. mallei* and *B. pseudomallei* is distinct from Inventions I-XVIII since it requires additional biological reagents and parameters.

Because these inventions are independent or distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark Navarro whose telephone number is (571) 272-0861.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Mark Navarro  
Primary Examiner  
March 9, 2006